Pfizer Inc. is boosting its pipeline with a $5.4 billion deal for blood disorder drugmaker Global Blood Therapeutics, the latest in a series of acquisitions to combat a potential slowdown in COVID-19 products demand as cases fall. Pfizer said on Monday it will pay $68.50 per share, representing a premium of 7.3 percent to Global…